The piroxicam complex of copper(II), trans-[Cu(Pir)2(THF)2], and its interaction with DNA

[1]  Xin Liu,et al.  DNA binding, oxidative DNA cleavage, cytotoxicity, and apoptosis-inducing activity of copper(II) complexes with 1,4-tpbd (N,N,N',N'-tetrakis(2-yridylmethyl)benzene-1,4-diamine) ligand. , 2011, Journal of inorganic biochemistry.

[2]  R. Ramaraj,et al.  Binding Interactions of Toluidine Blue O with Escherichia Coli DNA: Formation of Bridged Structure , 2011, Journal of Fluorescence.

[3]  S. Bhattacharya,et al.  Detailed spectroscopic investigations to reveal the nature of interaction of anionic porphyrin with calf thymus DNA. , 2010, Journal of photochemistry and photobiology. B, Biology.

[4]  F. Pessine,et al.  A theoretical and spectroscopic study of conformational structures of piroxicam. , 2010, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

[5]  Andrea E. Holmes,et al.  Interactions of a tetraanionic porphyrin with DNA: from a Z-DNA sensor to a versatile supramolecular device. , 2009, Journal of the American Chemical Society.

[6]  Ana Martínez.  Do anionic gold clusters modify conventional hydrogen bonds? The interaction of anionic Au(n) (n = 2-4) with the adenine-uracil base pair. , 2009, The journal of physical chemistry. A.

[7]  M. Casolaro,et al.  Release studies from smart hydrogels as carriers for piroxicam and copper(II)-oxicam complexes as anti-inflammatory and anti-cancer drugs. X-ray structures of new copper(II)-piroxicam and -isoxicam complex molecules. , 2008, Journal of inorganic biochemistry.

[8]  F. Ahmadi,et al.  In vitro study of DNA interaction with clodinafop-propargyl herbicide. , 2008, DNA and Cell Biology.

[9]  S. Arunachalam,et al.  DNA interaction of some polymer-copper(II) complexes containing 2,2'-bipyridyl ligand and their antimicrobial activities. , 2008, Journal of inorganic biochemistry.

[10]  G. Sheldrick.  A short history of SHELX. , 2008, Acta crystallographica. Section A, Foundations of crystallography.

[11]  A. Rodger,et al.  Synthetic metallomolecules as agents for the control of DNA structure. , 2007, Chemical Society reviews.

[12]  M. Sarkar,et al.  Direct binding of Cu(II)-complexes of oxicam NSAIDs with DNA backbone. , 2006, Journal of inorganic biochemistry.

[13]  G. Psomas,et al.  Mononuclear metal complexes with piroxicam: synthesis, structure and biological activity. , 2005, Journal of inorganic biochemistry.

[14]  C. Iyer,et al.  Absorption and fluorescence spectroscopy of 3-hydroxy-3-phenyl-1-o-carboxyphenyltriazene and its copper (II), nickel (II) and zinc (II) complexes: a novel fluorescence sensor , 2005 .

[15]  G. Mohamed,et al.  Synthesis, investigation and spectroscopic characterization of piroxicam ternary complexes of Fe(II), Fe(III), Co(II), Ni(II), Cu(II) and Zn(II) with glycine and DL-phenylalanine. , 2004, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

[16]  M. Zayed,et al.  Structure investigation, spectral, thermal, X-ray and mass characterization of piroxicam and its metal complexes. , 2004, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

[17]  V. McKee,et al.  Structural characterization and SOD activity of copper–oxaprozinate , 2004 .

[18]  John R. Miller,et al.  Crystallographic report: diphenylbis(hpiroxicam)tin(IV), Ph2Sn(Hpir)(2) , 2004 .

[19]  Hoo-Kyun Choi,et al.  Enhanced Percutaneous Absorption of Piroxicam via Salt Formation with Ethanolamines , 2002, Pharmaceutical Research.

[20]  Zhi-lin Wang,et al.  A dioxotetraamine fluorenyl ligand and its nickel(II) complex — crystal structure and fluorescent sensing properties in aqueous solution , 2001 .

[21]  I. Oh,et al.  Effects of non-ionic surfactants as permeation enhancers towards piroxicam from the poloxamer gel through rat skins. , 2001, International journal of pharmaceutics.

[22]  M. M. Abd-Elzaher.  Spectroscopic Characterization of Some Tetradentate Schiff Bases and Their Complexes with Nickel, Copper and Zinc , 2001 .

[23]  S. Belinsky,et al.  Cyclooxygenase-2 expression is abundant in alveolar type II cells in lung cancer-sensitive mouse strains and in premalignant lesions. , 2000, Carcinogenesis.

[24]  K. Seibert,et al.  Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. , 2000, Cancer research.

[25]  G. Amidon,et al.  Setting bioequivalence requirements for drug development based on preclinical data: optimizing oral drug delivery systems. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[26]  M. Méndez-Rojas,et al.  Direct electrosynthesis of Cu, Cd, Zn complexes of piroxicam (4-hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide-1,1,-dioxide) and isoxicam (4-hydroxy-2-methyl-N-(5-methyl-3-isoxazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide) in nonaqueous media by in-situ generation of supp , 1999 .

[27]  R. Cini,et al.  Synthesis of platinum(II)–piroxicam compounds. Crystal structure of trans-dichloro(η2-ethene)(piroxicam)platinum(II)‡ , 1998 .

[28]  B. Nordén,et al.  Short-Circuiting the Molecular Wire: Cooperative Binding of Δ-[Ru(phen)2dppz]2+ and Δ-[Rh(phi)2bipy]3+ to DNA , 1997 .

[29]  J. Rohovec,et al.  Complexes of platinum( II ) and palladium( II ) with aminomethylphosphonic acid and glycylaminomethylphosphonic acid , 1997 .

[30]  M. Dinger,et al.  Platinum(II), palladium(II), andnickel(II) thiosalicylate complexes , 1997 .

[31]  J. M. Weaver,et al.  Platinum(II) complexes catalyze reactions between platinum(IV) complexes and 9-methylxanthine‡ , 1997 .

[32]  R. Cini,et al.  The first crystal structure of a rhodium complex with the antileukaemicdrug purine-6-thione; synthesis and molecular orbital investigation ofnew organorhodium(III) compounds‡ , 1997 .

[33]  J. Reedijk.  Improved understanding in platinium antitumour chemistry , 1996 .

[34]  N. Berova,et al.  Circular Dichroism: Principles and Applications , 1994 .

[35]  M. Sporn.  Chemoprevention of cancer. , 1993, Lancet.

[36]  S. Etcheverry,et al.  Vibrational spectra of the copper(II) and nickel(II) complexes of piroxicam , 1993 .

[37]  C. Rossi,et al.  Metal complexes of the antiinflammatory drug piroxicam , 1990 .

[38]  J. Bordner,et al.  Deuterium isotope effects on carbon-13 NMR shifts and the tautomeric equilibrium in N-substituted pyridyl derivatives of piroxicam , 1989 .

[39]  N. Turro,et al.  Mixed-ligand complexes of ruthenium(II): factors governing binding to DNA , 1989 .

[40]  A. Wolfe,et al.  Polycyclic aromatic hydrocarbons physically intercalate into duplex regions of denatured DNA. , 1987, Biochemistry.

[41]  J. Lakowicz.  Principles of fluorescence spectroscopy , 1983 .

[42]  P. Ross,et al.  Thermodynamics of protein association reactions: forces contributing to stability. , 1981, Biochemistry.

[43]  L. Minchenkova,et al.  Different conformations of double‐stranded nucleic acid in solution as revealed by circular dichroism , 1973, Biopolymers.

[44]  J. Lombardino,et al.  Sudoxicam and related N-heterocyclic carboxamides of 4-hydroxy-2H-1,2-benzothiazine 1,1-dioxide. Potent nonsteroidal antiinflammatory agents. , 1972, Journal of medicinal chemistry.

[45]  R. Schnitzer.  Medicinal chemistry. Second edition: Edited by Alfred Burger, Professor of Chemistry, University of Virginia, Charlottesville. Interscience Publishers, Inc. New York, London. 1960. XIV + 1243 pp. $37.50 , 1961 .